PremiumRatingsSatellos Bioscience: Buy Rating Backed by Promising Clinical Progress and Robust Financial Position Satellos Bioscience Advances DMD Therapy with Promising Trial Results MSCLF Upcoming Earnings Report: What to Expect? PremiumThe FlySatellos Bioscience price target raised to C$1.25 from C$1 at Canaccord Satellos Bioscience Secures $40 Million Funding Boost Satellos Bioscience Announces Public Offering of Shares PremiumCompany AnnouncementsSatellos Bioscience Strengthens Board with Key Appointment Satellos Bioscience Advances in DMD Treatment Trials Satellos Bioscience to Attend Key Investor Conferences